The Effect of Genetic Variants Associated With Age-Related Macular Degeneration Varies With Age.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
entrez:
15
12
2020
pubmed:
16
12
2020
medline:
13
5
2021
Statut:
ppublish
Résumé
The prevalence of age-related macular degeneration (AMD) increases dramatically with age. This large collaborative study investigates the effects of 51 late-AMD-associated genetic variants in different ages, focusing on individuals above the age of 90 years. The study included 27,996 individuals of the International AMD Genomics Consortium; 14,539 showed late AMD (51.9%) and 13,457 were controls (48.1%). Four age groups were compiled: 60 to 69 years, n = 6514, AMD = 2210 (33.9%); 70 to 79 years, n = 12228, AMD = 6217 (51.7%); 80 to 89 years, n = 8285, AMD = 5326 (64.3%); and ≥90 years, n = 969, AMD = 686 (70.8%). The effect sizes of 51 AMD-associated genetic variants were calculated for all age groups and were compared among the age groups. Six variants were associated with late AMD in individuals ≥ 90 years of age (P ≤ 0.0006). For rs10922109 and rs570618 (both in CFH), the minor allele (MA) was protective, and minor allele frequency (MAF) increased with age in cases and controls. For rs116503776 in C2/CFB/SKIV2L, the MA was protective, and MAF increased in cases. For rs3750846 in ARMS2/HTRA1, the MA increased risk, and MAF was lower in cases with increasing age. For rs6565597 in NPLOC4/TSPAN10, the MA increased risk. For rs5754227 in SYN3/TIMP3, the MA was protective, and there was no consistent variation in MAF with age. Variants in CFH and ARMS2 showed lower effect sizes at greater age. Interaction analysis showed strong age-related effects for rs570618 (P = 2.24 × 10-7) and rs3750846 (P = 0.001). Total genetic risk was lower in individuals ≥ 90 years old (area under the curve [AUC], 0.795) than in those 70 to 79 years old (AUC, 0.831; P = 0.03). Effect sizes and MAF of genetic risk factors for late AMD differed among the age groups. These results could guide future work on AMD risk assessment in older individuals.
Identifiants
pubmed: 33320170
pii: 2772065
doi: 10.1167/iovs.61.14.17
pmc: PMC7745630
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Subventions
Organisme : NEI NIH HHS
ID : R01 EY022310
Pays : United States
Références
Nature. 2010 Mar 25;464(7288):504-12
pubmed: 20336132
Ophthalmic Epidemiol. 2017 Jun;24(3):141-152
pubmed: 28139151
Nat Genet. 2016 Feb;48(2):134-43
pubmed: 26691988
Genome Med. 2017 Mar 27;9(1):29
pubmed: 28347358
Ophthalmology. 2015 Feb;122(2):382-90
pubmed: 25264026
Ophthalmology. 2017 Dec;124(12):1753-1763
pubmed: 28712657
JAMA Ophthalmol. 2019 Mar 1;137(3):248-257
pubmed: 30570662
Acta Ophthalmol. 2012 Sep;90(6):e500-1
pubmed: 22268633
PLoS One. 2012;7(5):e37979
pubmed: 22666427
Ophthalmology. 2018 Apr;125(4):512-521
pubmed: 29153456
Hum Mol Genet. 2017 Oct 1;26(R2):R246
pubmed: 28977452
Aging (Albany NY). 2017 Dec 6;9(12):2504-2520
pubmed: 29227965
Genet Med. 2016 Apr;18(4):283-9
pubmed: 26020418
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
PLoS One. 2011 Mar 24;6(3):e17784
pubmed: 21455292
Ophthalmology. 2011 Nov;118(11):2203-11
pubmed: 21959373
Hum Mol Genet. 2012 Dec 1;21(23):5229-36
pubmed: 22936692
Philos Trans R Soc Lond B Biol Sci. 2011 Jan 12;366(1561):35-42
pubmed: 21115528
Elife. 2019 Jan 15;8:
pubmed: 30642433
Nature. 2012 Nov 1;491(7422):56-65
pubmed: 23128226
Aging Cell. 2013 Apr;12(2):184-93
pubmed: 23286790
Invest Ophthalmol Vis Sci. 2009 May;50(5):2044-53
pubmed: 19117936
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Graefes Arch Clin Exp Ophthalmol. 2014 Aug;252(8):1273-81
pubmed: 24970616
Invest Ophthalmol Vis Sci. 2014 Mar 25;55(3):1842-7
pubmed: 24576882
Prog Retin Eye Res. 2016 Sep;54:64-102
pubmed: 27156982